Development of dopaminergic and estrogenic control of prolactin release in the female rat

Sergio Ojeda, S. M. McCann

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

Plasma prolactin as determined by radioimmunoassay was barely detectable in 21 day old fetuses and on the day of birth (day 0). It had declined by days 3-6 and then rose gradually to attain adult levels at day 35. To evaluate further the development of the prolactin control system, the ability of estrogen to elicit prolactin release was studied at various ages by injecting different doses of estradiol benzoate (Eb) SC once daily for 2 days and measuring plasma prolactin 24 hr after the last injection. At 11 days of age, there was no significant increase in prolactin with any of the doses of Eb used (0.05-0.4 μg/100 g body wt). In 27 day old rats, the 0.4 μg dose induced a dramatic rise in plasma prolactin and the 0.05, 0.10 and 0.2 μg dose induced much smaller but significant increases in prolactin. By 37 days, the 0.2 μg dose became highly effective and the 0.4 μg dose induced an even larger increase. The response of adult females to this dose was significantly less than that observed in 37 day old animals. In a subsequent experiment, the time of first response to estrogen was determined more exactly to be 24 days of age. The maturation of the dopaminergic inhibitory control of prolactin release was studied by injecting the dopamine (DA) receptor blocker, Pimozide (0.63 mg/kg, SC), at different ages. The drug significantly elevated plasma prolactin as early as the third day of life and the magnitude of this response then increased progressively up to 35 days of age. It is suggested that plasma prolactin levels during development in the female rat depend on the balance between the stimulatory effect of estrogen on prolactin release and the inhibitory control exerted by the hypothalamic dopaminergic system.

Original languageEnglish (US)
Pages (from-to)1499-1505
Number of pages7
JournalEndocrinology
Volume95
Issue number6
StatePublished - 1974
Externally publishedYes

Fingerprint

Prolactin
Estrogens
Pimozide
Dopamine Antagonists
Dopamine Receptors
Radioimmunoassay
Fetus
Parturition
Injections

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Development of dopaminergic and estrogenic control of prolactin release in the female rat. / Ojeda, Sergio; McCann, S. M.

In: Endocrinology, Vol. 95, No. 6, 1974, p. 1499-1505.

Research output: Contribution to journalArticle

@article{6f6b0b72aa0d4583a0e9f6aee028f279,
title = "Development of dopaminergic and estrogenic control of prolactin release in the female rat",
abstract = "Plasma prolactin as determined by radioimmunoassay was barely detectable in 21 day old fetuses and on the day of birth (day 0). It had declined by days 3-6 and then rose gradually to attain adult levels at day 35. To evaluate further the development of the prolactin control system, the ability of estrogen to elicit prolactin release was studied at various ages by injecting different doses of estradiol benzoate (Eb) SC once daily for 2 days and measuring plasma prolactin 24 hr after the last injection. At 11 days of age, there was no significant increase in prolactin with any of the doses of Eb used (0.05-0.4 μg/100 g body wt). In 27 day old rats, the 0.4 μg dose induced a dramatic rise in plasma prolactin and the 0.05, 0.10 and 0.2 μg dose induced much smaller but significant increases in prolactin. By 37 days, the 0.2 μg dose became highly effective and the 0.4 μg dose induced an even larger increase. The response of adult females to this dose was significantly less than that observed in 37 day old animals. In a subsequent experiment, the time of first response to estrogen was determined more exactly to be 24 days of age. The maturation of the dopaminergic inhibitory control of prolactin release was studied by injecting the dopamine (DA) receptor blocker, Pimozide (0.63 mg/kg, SC), at different ages. The drug significantly elevated plasma prolactin as early as the third day of life and the magnitude of this response then increased progressively up to 35 days of age. It is suggested that plasma prolactin levels during development in the female rat depend on the balance between the stimulatory effect of estrogen on prolactin release and the inhibitory control exerted by the hypothalamic dopaminergic system.",
author = "Sergio Ojeda and McCann, {S. M.}",
year = "1974",
language = "English (US)",
volume = "95",
pages = "1499--1505",
journal = "Endocrinology",
issn = "0013-7227",
publisher = "The Endocrine Society",
number = "6",

}

TY - JOUR

T1 - Development of dopaminergic and estrogenic control of prolactin release in the female rat

AU - Ojeda, Sergio

AU - McCann, S. M.

PY - 1974

Y1 - 1974

N2 - Plasma prolactin as determined by radioimmunoassay was barely detectable in 21 day old fetuses and on the day of birth (day 0). It had declined by days 3-6 and then rose gradually to attain adult levels at day 35. To evaluate further the development of the prolactin control system, the ability of estrogen to elicit prolactin release was studied at various ages by injecting different doses of estradiol benzoate (Eb) SC once daily for 2 days and measuring plasma prolactin 24 hr after the last injection. At 11 days of age, there was no significant increase in prolactin with any of the doses of Eb used (0.05-0.4 μg/100 g body wt). In 27 day old rats, the 0.4 μg dose induced a dramatic rise in plasma prolactin and the 0.05, 0.10 and 0.2 μg dose induced much smaller but significant increases in prolactin. By 37 days, the 0.2 μg dose became highly effective and the 0.4 μg dose induced an even larger increase. The response of adult females to this dose was significantly less than that observed in 37 day old animals. In a subsequent experiment, the time of first response to estrogen was determined more exactly to be 24 days of age. The maturation of the dopaminergic inhibitory control of prolactin release was studied by injecting the dopamine (DA) receptor blocker, Pimozide (0.63 mg/kg, SC), at different ages. The drug significantly elevated plasma prolactin as early as the third day of life and the magnitude of this response then increased progressively up to 35 days of age. It is suggested that plasma prolactin levels during development in the female rat depend on the balance between the stimulatory effect of estrogen on prolactin release and the inhibitory control exerted by the hypothalamic dopaminergic system.

AB - Plasma prolactin as determined by radioimmunoassay was barely detectable in 21 day old fetuses and on the day of birth (day 0). It had declined by days 3-6 and then rose gradually to attain adult levels at day 35. To evaluate further the development of the prolactin control system, the ability of estrogen to elicit prolactin release was studied at various ages by injecting different doses of estradiol benzoate (Eb) SC once daily for 2 days and measuring plasma prolactin 24 hr after the last injection. At 11 days of age, there was no significant increase in prolactin with any of the doses of Eb used (0.05-0.4 μg/100 g body wt). In 27 day old rats, the 0.4 μg dose induced a dramatic rise in plasma prolactin and the 0.05, 0.10 and 0.2 μg dose induced much smaller but significant increases in prolactin. By 37 days, the 0.2 μg dose became highly effective and the 0.4 μg dose induced an even larger increase. The response of adult females to this dose was significantly less than that observed in 37 day old animals. In a subsequent experiment, the time of first response to estrogen was determined more exactly to be 24 days of age. The maturation of the dopaminergic inhibitory control of prolactin release was studied by injecting the dopamine (DA) receptor blocker, Pimozide (0.63 mg/kg, SC), at different ages. The drug significantly elevated plasma prolactin as early as the third day of life and the magnitude of this response then increased progressively up to 35 days of age. It is suggested that plasma prolactin levels during development in the female rat depend on the balance between the stimulatory effect of estrogen on prolactin release and the inhibitory control exerted by the hypothalamic dopaminergic system.

UR - http://www.scopus.com/inward/record.url?scp=0016299293&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0016299293&partnerID=8YFLogxK

M3 - Article

VL - 95

SP - 1499

EP - 1505

JO - Endocrinology

JF - Endocrinology

SN - 0013-7227

IS - 6

ER -